The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers
NCT ID: NCT06786403
Last Updated: 2025-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
70 participants
INTERVENTIONAL
2025-03-31
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
NCT02667327
The Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers
NCT04315909
Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
NCT00796744
Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers
NCT00632008
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers
NCT06402565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
placebo
Placebo
Placebo (1000 mg/day)
enteric-coated bromelain
Intervention : Bromelain
Bromelain
Dietary Supplement: Bromelain 1000 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bromelain
Dietary Supplement: Bromelain 1000 mg/day
Placebo
Placebo (1000 mg/day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with diabetic foot ulcers of category 0, 1 and 2 according to the Wagner criteria
* Patients aware of the study process for monitoring after filling out the informed consent form
Exclusion Criteria
* Pregnant and lactating women
* Severe kidney failure (GFR\<30)
* Severe liver failure (Child Pugh B, C)
* Patients with hemophilia
* People taking anticoagulant drugs, anti-platelet and thrombolytic
* Patients with irregular heartbeat and tachycardia
* Patients with asthma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Azita Hekmatdoost
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Azita Hekmatdoost
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mobina Tajdari, PharmD Student
Role: PRINCIPAL_INVESTIGATOR
Kamyab Andarzbakhsh, PharmD
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iran
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
162948239
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.